Amedisys — FY2018 Earnings Presentation
23 slides from Amedisys's earnings presentation, Feb 27, 2019
Slide 1: Fourth Quarter and Full Year 2018 Earnings Call Supplemental Slides
Amedisys Fourth Quarter and Full Year 2018 Earnings Call Supplemental Slides February 28th, 2019 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cau
Slide 3: A Look Back: FY 2018 Accomplishments
A Look Back FY 2018 Accomplishments (as compared to FY 2017 unless otherwise noted) Employer of Choice Reduced total voluntary turnover from 22.0% to 19.8% Successfully executed upon our Business Development strategy, exceeding 800 BD headcount (up from 759 as of 12/31/17) Outperformed industry benc
Slide 4: Our Key Areas of Focus
Our Key Areas of Focus Strategic areas of focus for Q4 2018 and beyond Home Health*: Total same store admission +6%. Total same store volume +6%. Total same store Medicare admits +3% Hospice: Admissions +12%, ADC +9% Personal Care: Double digit growth in billable hours / quarter +14% (including acqu
Slide 5: Highlights and Summary Financial Results (Adjusted): 4Q 2018
Highlights and Summary Financial Results (Adjusted): 4Q 2018(1) Home Health total same store volume +6%, total same store admissions +6%. Hospice same store admissions +12%. Personal Care +14% billable hours Amedisys Consolidated Revenue Growth: +9% EBITDA: $44M (+18%) EBITDA Margin: 10% (+80 bps) E
Slide 6: Our revenue sources: 4Q18
Our revenue sources: 4Q18 Medicare FFS: Paid episodically over a 60 day episode Private Episodic: MA and Commercial plans who pay us over a 60 day episode. Generally at rates ~90% – 100% of Medicare Per Visit: Managed care, Medicaid and private payors reimbursing us per visit provided Hospice Per Da
Slide 7: Home Health and Hospice Segment (Adjusted) – 4Q 2018
Home Health and Hospice Segment (Adjusted) – 4Q 2018(1) Medicare FFS growth +3.2% Revenue per Episode up +$33 Recert rate down 40 bps; +130 bps FY CPV flat in Q4’18 EBITDA as a % percentage of revenue: +110bps Q4; +190 bps FY’18 Home Health Highlights Same store average daily census (ADC) up 9% in 4
Slide 8: General & Administrative Expenses – Adjusted
General & Administrative Expenses – Adjusted (1,2) Notes: Year over year total G&A as a percentage of revenue decreased 110 basis points Home Health segment G&A: 140 bps decrease as % of revenue Hospice segment G&A: 20 bps increase as % of revenue Personal Care segment G&A: 240 bps decrease as % of
Slide 9: Industry Leading Quality Scores
Industry Leading Quality Scores Note: Top Competitor Avg weighted by CCN count and include LHC, Kindred, AFAM, HLS and BKD Metric OCT 18 Release JAN 19 Release APR 19 PREVIEW Quality of Patient Care 4.43 4.40 4.28 Entities at 4+ Stars 94% 94% 86% Metric JUL 18 Release OCT 18 Release JAN 19 Release P
Slide 10: Hospice Quality: Moving Towards Best-in-Class
Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality
Slide 11: Cost per Visit Components
Components 4Q’17 3Q’18 4Q’18 YoY Variance Detail Mitigation Plan Salaries $61.80 $61.93 $62.79 $0.99 YoY increase due to planned wage increases offset by volume growth and increased productivity Staffing mix optimization, productivity and scheduling improvement initiatives in place helped us overcom
Slide 12: Driving Top Line Growth
Driving Top Line Growth All three lines of business continue to grow. Hospice delivers another quarter of ADC growth and Home Health total same store volume continues to trend in the mid-single digits Home Health Total Same Store Volume* Hospice ADC Personal Care Total Hours / Quarter *Total Home He
Slide 13: Amedisys to acquire Compassionate Care Hospice
Amedisys to acquire compassionate care hospice Deal Summary Overview Metrics Integration Amedisys closes on its acquisition of Compassionate Care Hospice 100% stock purchase Compassionate Care Hospice: Founded in 1993 100% founder owned Average Daily Census: 3,300 Revenue: $188M Adj. EBITDA: $27M (T
Slide 14: Debt and Liquidity Metrics
Debt and Liquidity Metrics Our debt levels remain very low at (0.1)x net leverage. Pro forma for Compassionate Care Hospice, our leverage still remains low at ~1.6x net leverage Net debt defined as total debt outstanding ($10.9M) less cash balance ($20.2M). Leverage ratio (net) is defined as net deb
Slide 15: Cash Flow Statement Highlights
Cash Flow Statement Highlights (1) $62.8M in free cash flow for the quarter; $223.5M in cash flow from operations for the year up ~$118M from 2017 Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.
Slide 16: Income Statement Adjustments
Income Statement Adjustments (1) The financial results for the three-month periods ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018, and year ended December 31, 2018 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of
Slide 17: 2019 Guidance
2019 Guidance
Slide 18: Amedisys 2019 Preliminary Guidance
Amedisys 2019 Preliminary Guidance Targeting ~16% - 19% growth in revenue, ~13% - 16% growth in EBITDA and ~10% - 13% growth in EPS 2018 Actual Performance 2019 Guidance Revenue Adjusted EBITDA $180.6M $1.66B Adjusted Earnings per Share $3.63 $205M - $210M $1.94B - $1.98B $3.98 – $4.09
Slide 19: Amedisys 2019 Guidance Considerations
Amedisys 2019 Guidance Considerations Amedisys Consolidated Tax rate ~26% Cash tax rate ~17% Diluted share count ~33.1 million shares Capital Expenditures ~$8-$10 million Salary increase ~2% - 3% Benefits increase ~12% (8% growth / headcount, 4% pricing / claims costs) Overall ~$6 million investment
Slide 20: Compassionate Care Hospice (CCH) EBITDA Improvement
Compassionate Care Hospice (CCH) EBITDA Improvement HCHB disruption and investments in the business will impact EBITDA in 2019. EBITDA margin in 2020 and beyond will reflect legacy Amedisys hospice margin and growth trajectory Category Description ADC Disruption Negative impact on ADC as HCHB is ins
Slide 21: Reimbursement Outlook 2019
Reimbursement Outlook 2019 Reimbursement Impact for Home Health and Hospice Home Health Hospice 2019 Market Basket Update 3.0% Productivity Adjustment (0.8)0 Estimated Industry Impact +2.2% Estimated AMED-Specific Impact +1.2% 2019* Market Basket Update 2.9% Productivity / Other Adjustment (1.1) Est
Slide 22: EBITDA Seasonality: As Reported
EBITDA Seasonality: As Reported Q1 Q2 Q3 Q4 Drivers of Seasonality Weather disruption Lower RPE (LUPA) Payroll tax reset Short Month (Feb.) Lower Hospice ADC & Higher Salary Cost per Day Highest Completed Episodes Stronger revenue per episode (RPE) Incremental holiday vs. 1H High PTO Lower Volumes H
Slide 23: EBITDA Seasonality: Excluding Health Insurance and Workers Compensation
EBITDA Seasonality: Excluding Health Insurance and Workers Compensation Q1 Q2 Q3 Q4 Drivers of Seasonality Weather disruption Lower RPE (LUPA) Payroll tax reset Short Month (Feb.) Lower Hospice ADC & Higher Salary Cost per Day Highest Completed Episodes Stronger revenue per episode (RPE) Incremental